The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00640523




Registration number
NCT00640523
Ethics application status
Date submitted
17/03/2008
Date registered
21/03/2008
Date last updated
23/01/2012

Titles & IDs
Public title
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
Scientific title
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
Secondary ID [1] 0 0
BCX1777-210
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Lymphocytic Leukemia (CLL) 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - forodesine HCl

Treatment: Drugs: forodesine HCl
2 x 100mg capsules daily

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall response rate
Timepoint [1] 0 0
Up to 6 cycles of therapy

Eligibility
Key inclusion criteria
1. Age 18 years and older

2. Diagnosis of CLL established by peripheral blood and/or bone marrow examination and
using the standard diagnostic criteria.

3. Subjects with Rai stage III or IV, or earlier stage requiring therapy as determined by
the 1996 National Cancer Institute -Working Group (NCI-WG) criterion

4. Primary resistant (no CR or PR) or progressive disease after response to at least one
prior treatment regimen OR treatment naïve subjects who meet at least one of the
following criteria.

1. age >65 years

2. Eastern Cooperative Oncology Group (ECOG) performance status of 2, 3, or 4

3. Inability to tolerate standard cytotoxic chemotherapy in the opinion of the
treating physician.

5. ECOG performance status of 0, 1, or 2 (for subjects with primary resistance or
progressive disease after response to at least one prior treatment regimen).

6. Willing to take adequate contraceptive measures (i.e., latex condom, cervical cap,
diaphragm, abstinence, etc.) for the entire duration of the study and 3 months after,
except for patients who are post menopausal or have prior hysterectomy.

7. All investigational treatments should have been discontinued for at least 3 weeks
prior to the initiation of the study drug.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Pregnant or nursing.

2. Unable or unwilling to sign consent.

3. Severe, ongoing co-morbid conditions, which would preclude safe delivery of the
investigational therapy.

4. Active serious infections that are not controlled by antibiotics.

5. ECOG performance status >2 (except for treatment naïve subjects where ECOG performance
status 0, 1 or 5 is excluded).

6. Inadequate renal function: creatinine > or equal to 2.0 unless related to the disease.

7. Inadequate liver function: bilirubin > or equal to 3.0; transaminases > or equal to
3.0 times the upper limit of normal unless related to the disease.

8. Known positive test for human immunodeficiency virus (HIV).

9. Subjects with known hepatitis B and/or hepatitis C active infection.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Royal Brisbane and Women's Hospital - Brisbane
Recruitment hospital [2] 0 0
Frankston Hospital - Frankston
Recruitment hospital [3] 0 0
Cabrini Hospital - Malvern
Recruitment postcode(s) [1] 0 0
4029 - Brisbane
Recruitment postcode(s) [2] 0 0
3199 - Frankston
Recruitment postcode(s) [3] 0 0
3144 - Malvern
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Indiana
Country [3] 0 0
United States of America
State/province [3] 0 0
Maryland
Country [4] 0 0
United States of America
State/province [4] 0 0
Missouri
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Oregon

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
BioCryst Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To evaluate the effectiveness and safety of forodesine in CLL patients
Trial website
https://clinicaltrials.gov/show/NCT00640523
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Asher Chanan-Khan, MD
Address 0 0
Roswell Park Cancer Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications